

Ankylosing spondylitis (AS) and Non-radiographic axial spondyloarthritis (nr-AxSpA) Prescribing Pathway

Document control

Date	Version	Amendments
Nov 2023	2.0	Pathway developed in accordance with NCL 'Principles for Commissioning High-Cost Drug Pathways for ICB Commissioned Indications' and includes relevant published NICE TAs.
Apr 2024	3.0	Minor typos corrected Link to BSR guidance reference added and abbreviations corrected to full drug names. RAG rating definition amended to clarify that the rating is based on cost and not cost-effectiveness. Reference to secukinumab dose escalation removed as funding for this has not been confirmed.

Groups / Individuals who have overseen the development of this guidance:	UCLH Lead Pharmacist, Formulary & Clinical Trials, UCLH Specialised Commissioning Lead Pharmacist, NCL ICB Medicines Management Team, NCL Joint Formulary Principal Pharmacist, NCL Specialist Clinicians
Groups which were consulted and have given approval:	NCL wide consultation (NCL ICB, NCL Formulary Pharmacists, NCL Specialist Clinicians), NCL Joint Formulary Committee (Nov 2023), NCL Integrated Medicines Optimisation Board (Nov 2023)
File name:	Ankylosing Spondylitis Prescribing Pathway
Version number:	3.0
Available on:	
Disseminated to:	NCL Joint Formulary Committee, NCL Formulary Pharmacists, NCL Commissioners, NCL Specialist Clinicians
Equality impact assessment:	Low risk
NCL JFC Approval date:	November 2023
Review date:	November 2026 (or sooner if updates required e.g. NICE TAs)

Disclaimer

This guideline is registered at North Central London (NCL) Joint Formulary Committee (JFC) and is intended solely for use by healthcare professionals to aid the treatment of patients within NCL. However, clinical guidelines are for guidance only, their interpretation and application remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Clinicians are advised to refer to the manufacturer's current prescribing information before treating individual patients.

The authors and NCL JFC accept no liability for use of this information beyond its intended use.

While we have tried to compile accurate information in this guideline, and to keep it updated in a timely manner, we cannot guarantee that it is fully complete and correct at all times. If you identify information within this guideline that is inaccurate, please report this to the admin.ncl-mon@nhs.net. If a patient is harmed as a consequence of following this guideline, please complete a local incident report and inform admin.ncl-mon@nhs.net.

This guideline should not be used or reproduced for commercial or marketing purposes.

NCL JFC is funded by and provides advice to Acute Trusts and the Integrated Care Board in NCL.

Ankylosing spondylitis (AS) and Non-radiographic axial spondyloarthritis (nr-AxSpA) Prescribing Pathway

Green: lowest cost **Amber:** moderate cost **Red:** highest cost.

If more than one treatment is suitable, the least expensive treatment should be used.

Criteria to start treatment for Ankylosing spondylitis (AS) / Non-radiographic axial spondyloarthritis (nr-AxSpA):

AS: Severe active ankylosing spondylitis with confirmed X-ray changes showing sacroiliitis

nr-AxSpA: Severe non-radiographic axial spondyloarthritis with confirmed MRI changes or no MRI changes with a positive HLA-B27 test and ≥ 2 clinical features of axial SpA

- Inadequate response to ≥ 2 NSAIDs at the maximum tolerated dose for 2-4 weeks each (unless not tolerated due to contraindications/toxicity) **and**;
- Sustained active spinal disease demonstrated by a Bath Ankylosing Spondylitis Disease Activity (BASDAI) score ≥ 4 units and spinal pain visual analogue score (VAS) ≥ 4cm

1ST LINE TREATMENT OPTIONS

TNF inhibitor:

Adalimumab SC (Preferred) OR
Etanercept SC OR Infliximab SC/IV biosimilars [TA383; infliximab for AS only]

Certolizumab (TA383) and golimumab (TA383/TA497) also available but not preferred.

Upadactinib (TA829/TA861), tofacitinib (TA920), secukinumab (TA407/TA719), ixekizumab (TA718), bimekizumab (TA918) and are available 1st line if TNF inhibitor not suitable¹ or contraindicated².

2ND LINE ONWARDS TREATMENT OPTIONS

Alternative TNF inhibitor:

Adalimumab SC OR **Etanercept SC** OR **Infliximab IV/SC** biosimilars [TA383; infliximab for AS only]

Certolizumab (TA383) and golimumab (TA383/TA497) also available but not preferred

JAK inhibitor:

Upadactinib [TA829/TA861]
NB. [MHRA update](#)

Tofacitinib (TA920) also available but not preferred³.

IL17 inhibitor:

Secukinumab [TA407/TA719]

Ixekizumab (TA718) and bimekizumab (TA918) also available but not preferred⁴.

Sequential treatments routinely commissioned: Up to one drug per mechanism of action, plus a second TNF inhibitor. If more than one treatment is suitable, the least expensive treatment should be used.

Drug	Price	Usual maintenance	Additional Information
Adalimumab	£	40mg SC every 2 weeks	
Etanercept	£	25mg SC twice weekly, or 50mg SC every weekly	Preferred TNF inhibitor for IGRA +ve patients
Infliximab	£	120mg SC once every 2 weeks 5mg/kg IV every 8 weeks	For Ankylosing Spondylitis only
Upadactinib	££	15mg daily	
Tofacitinib	££	5mg twice daily	
Secukinumab	££	150mg monthly	
Certolizumab	£££	200mg every 2 weeks	
Bimekizumab	£££	160mg every 4 weeks	
Ixekizumab	£££	80mg every 4 weeks	
Golimumab	£££	50mg every 4 weeks	In patients weighing >100Kg who do not achieve adequate clinical response after 3-4 x 50mg doses, dose can be increase to 100mg/month taking into account the increased risk of serious adverse drug reactions. Continued therapy should be reconsidered if there is not therapeutic benefit after 3-4 additional doses of 100mg

Assessment of response - Assess initial induction response according to NICE TA timeframes (12-20 weeks). Treatment response is defined as:

- A reduction in the BASDAI score to 50% of pre-treatment value or by ≥ 2 **and**
- A reduction in the spinal pain VAS by ≥ 2 cm

Continuation of biologic treatment – Treat for 6 months or until treatment failure. Reassess at 6 monthly intervals to determine whether ongoing treatment is still clinically appropriate. Following 24 months of stable treatment, consider annual reviews.

Adverse drug reactions (ADRs) – For patients who experience an immediate ADR [within 1 month] or have responded to treatment but experience an ADR within 6 months of treatment initiation, another treatment option within the same mechanism of action (if available and appropriate) can be accessed. Where the ADR is likely to be a drug class effect, an alternative mechanism of action is preferable.

Dual biologic therapy for the same disease is not routinely commissioned; for individual cases, please consider [RMOC advisory statement](#), discuss at MDT and contact Trust formulary teams for advice re IFR submission. **Concurrent biologic treatment for different co-morbidities**, is permissible provided NICE eligibility criteria for both treatments are met and there is MDT agreement across both specialities that dual therapy is appropriate and a single drug which is active against both co-morbidities is not available.

Treatment breaks & dose reductions – patients who reduce dose or hold biologic treatment can resume the standard biologic regimen (i.e. licensed dose), with an assessment of response made at 12-20 weeks.

Pregnancy – updated [guidance from BSR](#)

- Women with no/low disease activity established on a TNF inhibitor with known placental transfer (infliximab, adalimumab, golimumab) do not need to be switched to an alternative TNF inhibitor with established minimal placental transfer (certolizumab) either before or during pregnancy (GRADE 1B, Strength of agreement 100%).
- Certolizumab is compatible with all three trimesters of pregnancy, has no to minimal placental transfer compared with other TNF inhibitor, and does not require any alteration to the infant vaccination schedule (GRADE 1B, Strength of agreement 100%).
- Women considered to have low risk of disease flare on withdrawal of TNF inhibitor in pregnancy could stop infliximab at 20 weeks, adalimumab and golimumab at 28 weeks, and etanercept at 32 weeks so that a full-term infant can have a normal vaccination schedule, with rotavirus vaccination at 8 weeks as per the UK schedule (GRADE 1B, Strength of agreement 99.5%).
- Infliximab, adalimumab, etanercept or golimumab may be continued throughout pregnancy to maintain maternal disease control; in these circumstances, live vaccines should be avoided in infants until they are 6 months of age (GRADE 1B, Strength of agreement 100%).
- If a TNF inhibitor is stopped in pregnancy, it can be restarted as soon as practical post-partum in the absence of infections or surgical complications, regardless of breastfeeding status, to ensure control of maternal disease (GRADE 1C, Strength of agreement 100%).

Footnotes

¹ Clinically patients with very severe concurrent psoriasis (unstable disease and rapid response required) may require treatment with IL-17 as a first line agent. Refer to NCL Psoriasis pathway.

² Relative contraindications to TNF inhibitors include: current malignancy, history of malignancy, recurrent infections, history of demyelinating disorders, interstitial lung disease, moderate to severe heart failure (NYHA class III/IV), systemic lupus erythematosus, and positive antinuclear antibodies (ANA).

³ Upadacitinib is the preferred JAK inhibitor because it is the lowest-cost and there is no evidence that other JAKi have superior efficacy [doi: [10.1159/000525627](https://doi.org/10.1159/000525627)].

⁴ Secukinumab is the preferred IL-17 inhibitor it is the lowest-cost and there is no evidence that other IL-17 inhibitor have superior efficacy [[NICE FAD for bimekizumab](#), see *Why these recommendations were made*].

References

[British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids](#)